Abstract
Introduction Intradermal (ID) vaccination may alleviate COVID-19 vaccine shortages and vaccine hesitancy due to systemic reactogenicity among older adults.
Objectives To compare the immunogenicity and reactogenicity of fractional ID and standard intramuscular (IM) booster vaccination of mRNA-1273 and BNT162b2 vaccines in older adults.
Methods Participants aged ≥65 years who previously vaccinated with 2-dose ChAdOx1 were randomized to receive one of the four booster vaccinations: 0.1mL ID mRNA-1273, 0.5mL IM mRNA-1273, 0.1mL ID BNT162b2 and 0.3mL IM BNT162b2. Immunogenicity as measured by anti-receptor binding domain (anti-RBD) IgG against Wuhan, neutralising antibody (NAb) against Wuhan and Omicron BA.1, BA.2 and BA.4/5, and IFNγ-producing cells. Local and systemic adverse effects (AEs) were self-reported via an electronic diary card.
Results Of the 210 participants enrolled, 70.5% were female and median age was 77.5 years (interquartile range (IQR): 71.0-84.0). Following the booster dose, both ID vaccination induced 37% lower levels of anti-RBD IgG than IM vaccination of the same vaccine. NAb against ancestral and Omicron BA.1 strains was highest following IM mRNA-1273 (1,718 and 617), followed by ID mRNA-1273 (1,212 and 318), IM BNT162b2 (713 and 230), and ID BNT162b2 (587 and 148), respectively. Spike-specific IFNγ responses were similar or higher in the ID groups when compared with their respective IM groups. Vaccine delivery through ID route tended to have lower systemic AEs, although more local AEs reported in ID mRNA-1273 group.
Conclusions Fractional ID vaccination induced immunogenicity and reactogenicity comparable to IM and may be an alternative option for older people.
Key points
Fractional dose intradermal mRNA COVID-19 booster vaccination induces robust immunogenicity in adults aged ≥65 years.
For each vaccine, intradermal route induced lower humoral but similar or higher cellular immune responses than IM route.
Intradermal mRNA-1273 vaccination induced similar immunogenicity to intramuscular BNT162b2 vaccination.
Immune responses were marginally lower among participants aged ≥80 years than among participants aged 65-79 years.
Systemic reaction was lower following intradermal mRNA COVID-19 vaccination compared with intramuscular vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
TCTR20220112002
Funding Statement
This study was supported by the Health Systems Research Institute (HSRI) (grant number 65-037). The funders had no role in the design of the study; collection, analysis and interpretation of the data; or writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Siriraj Institutional Review Board, Thailand (COA no. Si 001/2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Ethical Approval: This study was approved by the Institutional Review Boards of the Committee on Ethics, Faculty of Medicine Siriraj Hospital, Mahidol University (Certificate of Approval no. Si001/2022), and informed consent was obtained from all study participants.
Declaration of Conflicts of Interest: None.
Declaration of Sources of Funding: This study was supported by the Health Systems Research Institute (HSRI) (grant number 65-037). The funders had no role in the design of the study; collection, analysis and interpretation of the data; or writing of the manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
